Summary
Definition
MM is a malignant neoplasm of plasma cells. Myeloma cells proliferate and accumulate in the bone marrow and secrete abnormal (monoclonal) immunoglobulins or immunoglobulin fragments (known as a paraprotein or M-protein). This can result in complications such as hypercalcemia, osteolytic bone disease, renal failure, anemia, and infection.[1][2] [Figure caption and citation for the preceding image starts]: A: serum protein electrophoresis demonstrating a monoclonal immunoglobulin. B: serum and urine immunofixation electrophoresis (IFE) demonstrating a monoclonal immunoglobulin and free light chain (Bence Jones [BJ] protein)Courtesy of Dr M Murali and the Clinical Immunology Laboratory, Massachusetts General Hospital; used with permission [Citation ends].
History and exam
Key diagnostic factors
- anemia
- bone pain
- monoclonal gammopathy of undetermined significance (MGUS)
Other diagnostic factors
- hypercalcemia
- infections
- fatigue
- renal impairment
Risk factors
- monoclonal gammopathy of undetermined significance (MGUS)
- abnormal free light-chain ratio
- male sex
- black ethnicity
- family history of MM
- radiation exposure
- petroleum products exposure
Diagnostic tests
1st tests to order
- serum quantitative immunoglobulins
- serum/urine protein electrophoresis
- serum/urine immunofixation
- serum free light-chain assay
- whole-body, low-dose CT (WBLD-CT)
- 18F-fluorodeoxyglucose-positron emission tomography/CT (FDG-PET/CT)
- bone marrow evaluation
- serum calcium
- CBC with differential
- peripheral blood smear
- serum creatinine, BUN, electrolytes
- serum uric acid
- liver function tests
- C-reactive protein (CRP)
- serum lactate dehydrogenase (LDH)
- serum beta2-microglobulin
- serum albumin
- N-terminal prohormone of brain natriuretic peptide (NT-proBNP) or BNP
Tests to consider
- whole-body MRI
- skeletal survey
- cytogenetic analysis
- mass spectrometry
- genetic testing
- serum viscosity
- viral infection screening
Treatment algorithm
newly diagnosed transplant candidates
newly diagnosed nontransplant candidates
patients responding to initial treatment
relapsing or refractory disease
Contributors
Authors
Matthew M. Lei, PharmD
Clinical Pharmacist Medical Oncology
Massachusetts General Hospital
Boston
MA
Disclosures
MML declares that he has no competing interests. MML is an author of a reference cited in this topic.
Diana Cirstea, MD
Medical Oncologist
Center for Multiple Myeloma
Massachusetts General Hospital
Harvard Medical School
Boston
MA
Disclosures
DC is on the advisory board for Sanofi.
E. Bridget Kim, PharmD, BCPS, BCOP
Clinical Pharmacist
Massachusetts General Hospital
Boston
MA
Disclosures
EBK declares that she has no competing interests.
Noopur Raje, MD
Director of Multiple Myeloma Program
Massachusetts General Hospital
Harvard Medical School
Boston
MA
Disclosures
NR has received institutional research funding from Amgen, bluebird bio, Janssen, Caribou, Bristol Myers Squibb, and Celgene. NR is an author of several references cited in this topic.
Acknowledgements
Dr Matthew M. Lei, Dr Diana Cirstea, Dr E. Bridget Kim, and Dr Noopur Raje would like to gratefully acknowledge Dr Loredana Santo and Dr Sonia Vallet, previous contributors to this topic.
Disclosures
LS and SV declare that they have no competing interests.
Peer reviewers
Shaji Kumar, MD
Associate Professor of Medicine
Mayo Clinic
Rochester
MN
Disclosures
SK declares that he has no competing interests.
Faith Davies, MD
Institute of Cancer Research
Sutton
Surrey
UK
Disclosures
FD declares that she has no competing interests.
Differentials
- Monoclonal gammopathy of undetermined significance
- Solitary plasmacytoma
- Waldenström macroglobulinemia
More DifferentialsGuidelines
- NCCN clinical practice guidelines in oncology: multiple myeloma
- NCCN clinical practice guidelines in oncology: hematopoietic cell transplantation
More GuidelinesPatient information
Multiple myeloma
More Patient information
Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer